March 5, 2026
Headlines

Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps

Sumain Faisal01 mins

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News